PTSM: Pharmaceutical Technology Sourcing and Management
With a new name formed from the legacy company names, Alcami offers development services, analytical testing, and API and finished drug development and manufacturing.
AAIPharma Services Corporation (AAI)/Cambridge Major Laboratories, Inc. (CML), announced on March 16, 2016 a new name and brand identity, Alcami, as a contract development and manufacturing organization for drug substance and finished drug products.
With seven sites globally, the company offers API development and manufacturing, solid-state chemistry, formulation development, analytical development and testing services, oral solid dose and parenteral clinical and commercial finished dosage form manufacturing, packaging, and stability services.
The new company name and identity were announced at press event and reception in New York City. The name “Alcami” represents a combination of the legacy company names and reflects the company’s transformation to meet the pipeline of new products in development within the pharmaceutical and biotech industries, the company reports.
AAI and CML, which merged in 2013, recently announced investments oral solid dose manufacturing and parenteral fill-finish capabilities and capacity. The company will relocate its St. Louis Analytical Testing Services to a new facility at the Cortex Innovation Center in St. Louis, MO; the facility will provide analytical testing for new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals, and biopharmaceuticals.
“With nearly 1000 employees at seven sites in the United States and Europe, these upgrades across our facilities in Wilmington (NC), Charleston (SC), Durham (NC), Germantown (WI), Edison (NJ), St. Louis, and Weert, The Netherlands, combined with enhancements in our quality, execution and customer focus, support the overall progress of our growth strategy as a contract services provider with a renewed commitment to meeting customer needs like never before. With increases in our capabilities and capacities across all our businesses, our ability to serve the market is stronger than ever,” said Stephan Kutzer, chief executive officer in a press statement announcing the new brand identity.
Source: Alcami
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.